TGFB1 and neoplasm: Crizotinib treatment could potentially lead to reduced Smad-mediated gene transcription, thereby inhibiting tumor cell invasion and metastasis, as supported by a recent study by Park et al. (2022), demonstrating its ability to suppress TGF-β signaling in NSCLC cells [41].